McKesson Corporation MCK reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of $8.03, which missed the ...

For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing public health issue of obesity in America" and ties in with the company's ...

GLP1 receptor agonists are widely prescribed to help control blood sugar levels and support weight loss. While these ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and Wegovy develop complications with their eyesight, highlighting that we ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The Princeton-based startup said the move was related to “a revenue mix shift within the Noom business" driven by a change in ...

For decades, the US healthcare system has struggled to address the diet-related chronic illnesses affecting nearly half of ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...